TY - JOUR
T1 - Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
AU - Faro-Viana, João
AU - Bergman, Marie Louise
AU - Gonçalves, Lígia A.
AU - Duarte, Nádia
AU - Coutinho, Teresa P.
AU - Borges, Patrícia C.
AU - Diwo, Christian
AU - Castro, Rute
AU - Matoso, Paula
AU - Malheiro, Vanessa
AU - Brennand, Ana
AU - Kosack, Lindsay
AU - Akpogheneta, Onome
AU - Figueira, João M.
AU - Cardoso, Conceição
AU - Casaca, Ana M.
AU - Alves, Paula M.
AU - Nunes, Telmo
AU - Penha-Gonçalves, Carlos
AU - Demengeot, Jocelyne
N1 - Funding Information:
We thank the healthcare workers and nursing home residents who participated in the study. We are indebted to Jorge Carneiro for help with ELISA data analysis and Tiago Paixão for guidance in the data processing. We are grateful to Joao Costa and Joana Bom for providing training on highly specialized equipment made available for this work. We acknowledge the serology4covid consortium for joined effort during the implementation of a low-scale pilot version of the ELISA assay. We also thank the healthcare professionals involved in the HCW sample collection and local testing: Inês Sousa, Catarina Farinha, Susana Vaz, Helena Fernandes, Carla Castro, Catarina Simões, Joana Soares, Nara Silva, Ana Matos, Isabel Barros and Inês Santos. We are indebted to the study assistants who ensured the NHR collection: Lara Fontes, Pureza Duarte Ferreira, Paulo Guia, Pedro Silva and João Ferreira. We are most thankful to all the members of the IGC-COVID-19 task force for their continuous support. We thank Antonio Coutinho and Thiago Carvalho for their critical reading of the manuscript. This work benefited from COVID-19 emergency funds 2020 from Calouste Gulbenkian Foundation (to C.P.G. and J.D.) and from Oeiras (to P.M.A.) and Almeirim (to T.N.) city councils. It was also supported by the Science and Technology Foundation, Ministry of Education and Science (FCT, Portugal) through the Project 754-Research4COVID-19– 2nd edition (to C.P.G.) and by PORLisboa 2020, Portugal 2020 and European Union, through European Regional Development Fund through the project FEDER/072558 (to J.D.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.
AB - While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.
UR - http://www.scopus.com/inward/record.url?scp=85122894477&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-27761-z
DO - 10.1038/s41467-021-27761-z
M3 - Article
C2 - 35013258
AN - SCOPUS:85122894477
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 140
ER -
